-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H2KbhU7kBsM07vxOOdpK9TmMPQ3ZNVF0wrLfqWJUTK4TH2x8dqsrCtDyyKu47KKe mvZp49j0kRblrxN3+mYp/w== 0000950116-05-002561.txt : 20050729 0000950116-05-002561.hdr.sgml : 20050729 20050729122326 ACCESSION NUMBER: 0000950116-05-002561 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050719 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20050729 DATE AS OF CHANGE: 20050729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMPAX LABORATORIES INC CENTRAL INDEX KEY: 0001003642 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650403311 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27354 FILM NUMBER: 05983610 BUSINESS ADDRESS: STREET 1: 30831 HAYWARD AVE CITY: HAYWARD STATE: CA ZIP: 94544 BUSINESS PHONE: 2152892220 MAIL ADDRESS: STREET 1: CASTOR & KENSINGTON AVENUES CITY: PHILADELPHIA STATE: PA ZIP: 19124-5694 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\ DATE OF NAME CHANGE: 19951117 8-K 1 eightk.txt 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 19, 2005 Impax Laboratories, Inc. - -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Its Charter)
Delaware 0-27354 65-0403311 - --------------------------------------------------------------------------------------------------------- (State or other jurisdiction (Commission File Number) (IRS Employer Identification No.) of incorporation) 30831 Huntwood Ave., Hayward, CA 94544 - --------------------------------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 476-2000 -------------- Not Applicable - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ITEM 7.01 REGULATION FD DISCLOSURE On July 19, 2005, the U.S. Patent and Trademark Office issued U.S. Patent #6,919,373 to Alza Corporation (Alza) with claims covering its Concerta(R) product. Concerta(R) is a registered trademark of Alza Corporation. This patent was listed in the Food and Drug Administration's (FDA) Electronic Orange Book (Orange Book) on July 19, 2005 and was the first time a patent relating to Concerta(R) had been listed in the Orange Book. On July 19, 2005, we filed a certification under Paragraph IV of the Hatch-Waxman Amendments with the FDA relating to this patent and notified Alza and related companies of such certification. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMPAX LABORATORIES, INC. Date: July 29, 2005 By: /s/ Arthur A. Koch, Jr. ------------------------------ Name: Arthur A. Koch, Jr. Title: Chief Financial Officer 3 -----END PRIVACY-ENHANCED MESSAGE-----